Ohio Plaintiff Files Actos Bladder Cancer Lawsuit
Cincinnati, Ohio resident John Merritt filed an Actos lawsuit on January 26, 2012 in the U.S. District Court for the Southern District of California. Merritt claims he developed Actos bladder cancer after relying on the popular drug to control his type II diabetes.
Jury trial demanded in Actos lawsuit
The plaintiff reportedly began taking Actos in 2001 and was diagnosed with bladder cancer in May of 2010. According to his Actos lawsuit complaint, Merritt was unaware that prolonged exposure to the drug, especially for periods in excess of twelve months, was associated with a high risk of developing Actos bladder cancer.
Merritt’s Actos lawyers allege that Takeda Pharmaceuticals, the manufacturer of the drug, knew about the risk of Actos bladder cancer, but concealed it from consumers and medical professionals.
Had Merritt been informed of the risk, his Actos lawyers contend, he would have sought safer alternatives to control his diabetes.
His seven-count Actos lawsuit seeks both compensatory and punitive damages for fraud, negligence, strict products liability, and negligent misrepresentation.
Actos bladder cancer linked to prolonged exposure
John Merritt’s Actos lawsuit is one of many that have been filed against Takeda Pharmaceuticals. Though Actos is one of Takeda’s best-selling drugs, with global sales of over $4 billion, many patient advocates have criticized the drug for its dangerous side effects.
Clinical evidence has shown that patients who use the medication for more than a year have a high risk of developing Actos bladder cancer. A 2011 study of data from the FDA’s Adverse Events Reporting System indicated “a definite signal for bladder cancer associated with (Actos) use” after six to 24 months.
Actos lawyers cite FDA review
On September 17, 2010, the FDA announced a review of preliminary data from the ongoing 10 year Actos bladder cancer study Takeda is undertaking at the health agency’s request.
An analysis of the interim data showed that the risk of Actos bladder cancer increases with longer durations of use and with larger doses of the drug.